65,437 trials
Asthma
Primary: Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population — 19.3; 26.9 Liters/Minute (L/min) — p=0.012
Obstructive Sleep Apnea (OSA)
Primary: PAP Treatment Efficacy — 4.2; 4.0 Events per hour
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Zoster Virus (VZV) Antibodies Above the Cut-off Values — 294; 155; 262; 145 Participants…
Influenza
Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants
Primary Myelofibrosis (PMF) · Post-Polycythaemia Vera · Essential Thrombocythaemia Myelofibrosis
Primary: Pharmacokinetic Parameters Following Single Dosing: AUC0-12 — 69.2; 295; 278; 1860 ug*h/L
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
Migraine
Primary: Pain-relief Response (Pain Severity of NONE or MILD) at 2 Hours — 20; 29; 34; 33 participants — p=0.0212
Ulcerative Colitis
Primary: To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC). — 42; 29 participants — p=0.069
Dermatitis, Atopic
Primary: Number of Participants With Local Tolerability Symptoms According to Severity on Baseline — 10; 7; 6; 0 participants
Healthy
Primary: Number of Participants With Positive Blood Culture for L Reuteri — 0; 0 Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib — 99.2; 76.8 nanograms/milliliter (ng/mL)
Respiratory Distress Syndrome
Primary: Peri-Dosing Events — 0; 0; 0; 1 participants
Pre-diabetes · Older Adults
Primary: Change in Weight Reported at 14 Weeks — -3.3; -6.8 kg — p=<0.05
Healthy Participants
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib — 626; 584; 297; 301 nanogram*hour/milliliter…
MELAS Syndrome
Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants